Nonvalvular Atrial Fibrillation
📧 Sign up to get email alerts when something new happens for Nonvalvular Atrial Fibrillation.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation
A clinical trial is evaluating the safety and therapy adherence of apixaban in patients with nonvalvular atrial fibrillation; the study is c…
-
CLINICAL_TRIALS other · 2026-03-06Clinical Trial Update: LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System for Patients With Non-Valvular Atrial Fibrillation [NA]
Clinical trial update for the LAmbre II Left Atrial Appendage Occluder and Occluder Delivery System in patients with nonvalvular atrial fibr…
-
FDA approval · 2025-10-07FDA Approved: RIVAROXABAN — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical's generic rivaroxaban under an original ANDA, for the same indications as the reference product (e.g., reduc…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation [NA]
This document provides an update on an early feasibility clinical trial evaluating the Laminar Left Atrial Appendage Closure System for nonv…
-
CLINICAL_TRIALS trial_result · 2025-09-16Clinical Trial Update: Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;
A real-world, prospective study evaluates the safety and effectiveness of apixaban in adults over 80 with nonvalvular atrial fibrillation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure [Phase 4]
Phase 4 trial evaluating non-antithrombotic therapy versus single antiplatelet therapy after left atrial appendage closure in nonvalvular at…
-
CLINICAL_TRIALS research · 2025-07-04Clinical Trial Update: Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry
This clinical trial registry update assesses safety and effectiveness of short-term single antiplatelet therapy after left atrial appendage …
-
FDA approval · 2025-06-26FDA Approved: RIVAROXABAN — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' generic rivaroxaban (RIVAROXABAN) under an Original Application, enabling a generic version of the anticoa…
-
FDA approval · 2025-05-15FDA Approved: RIVAROXABAN — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's original application for generic rivaroxaban, a direct oral anticoagulant.
-
FDA approval · 2025-05-14FDA Approved: RIVAROXABAN — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved an original application for rivaroxaban (generic) from XLCare Pharmaceuticals, Inc.
-
FDA approval · 2025-05-14FDA Approved: RIVAROXABAN — Original Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' original ANDA for rivaroxaban, making a generic rivaroxaban available in the U.S. for approved indic…
-
FDA approval · 2025-05-14FDA Approved: RIVAROXABAN — Original Application (Dr.Reddy's Laboratories, Inc.)
FDA approved Dr. Reddy's Laboratories' generic rivaroxaban for marketing (ANDA 208534), expanding access to the direct oral anticoagulant. T…
-
FDA approval · 2025-05-14FDA Approved: RIVAROXABAN — Original Application (Macleods Pharmaceuticals Limited)
The FDA approves Macleods Pharmaceuticals Limited's original (ANDA) application for rivaroxaban, a generic version of the anticoagulant.
-
FDA approval · 2025-05-14FDA Approved: RIVAROXABAN — Original Application (Changzhou Pharmaceutical Factory)
FDA approved the original application for rivaroxaban from Changzhou Pharmaceutical Factory under ANDA216995.
-
FDA approval · 2025-03-03FDA Approved: RIVAROXABAN — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved the original application for rivaroxaban from Sun Pharmaceutical Industries, confirming regulatory clearance for a generic riva…
-
FDA approval · 2025-02-24FDA Approved: DABIGATRAN ETEXILATE — Supplemental Application (XLCare Pharmaceuticals, Inc.)
FDA approves a supplemental application for XLCare Pharmaceuticals to market a generic dabigatran etexilate, covering its approved indicatio…
-
CLINICAL_TRIALS research · 2025-02-05Clinical Trial Update: Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR) [NA]
A Mayo Clinic-sponsored clinical trial WATCH-TMVR is evaluating the Watchman left atrial appendage occlusion device in patients with nonvalv…
-
FDA approval · 2025-02-03FDA Approved: DABIGATRAN ETEXILATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's original Abbreviated New Drug Application for dabigatran etexilate, enabling a generic version of this anticoagulant to…
-
FDA approval · 2025-01-28FDA Approved: DABIGATRAN ETEXILATE — Original Application (Dr.Reddys Laboratories Inc)
FDA approved Dr.Reddys Laboratories Inc for a generic version of dabigatran etexilate under an Original Application, making the product avai…
-
FDA approval · 2024-09-11FDA Approved: DABIGATRAN ETEXILATE — Original Application (Major Pharmaceuticals)
The FDA approved an original application for dabigatran etexilate (generic) from Major Pharmaceuticals. It covers indications such as nonval…
-
FDA approval · 2024-08-16FDA Approved: DABIGATRAN ETEXILATE — Supplemental Application (Major Pharmaceuticals)
The FDA approved a supplemental application for dabigatran etexilate (generic) submitted by Major Pharmaceuticals.
-
FDA approval · 2024-08-13FDA Approved: DABIGATRAN ETEXILATE — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved XLCare Pharmaceuticals' original application for dabigatran etexilate (generic), confirming a generic version of the anticoagul…
-
FDA approval · 2024-08-12FDA Approved: DABIGATRAN ETEXILATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' original application for dabigatran etexilate, a generic anticoagulant. It is used to reduce stroke ri…
-
FDA approval · 2024-06-14FDA Approved: DABIGATRAN ETEXILATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals' Original Application for dabigatan etexilate as a generic version of Pradaxa, an oral anticoagulant in…
-
FDA approval · 2024-05-22FDA Approved: DABIGATRAN — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original ANDA (ANDA213879) for DABIGATRAN (Dabigatan etexilate), a generic anticoagulant. The approval enables Novadoz Phar…